SELLAS Life Sciences Group, Inc. (SLS): Price and Financial Metrics

SELLAS Life Sciences Group, Inc. (SLS): $1.01

0.02 (-1.94%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

D

Add SLS to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#349 of 365

in industry

SLS Price/Volume Stats

Current price $1.01 52-week high $1.91
Prev. close $1.03 52-week low $0.50
Day low $0.99 Volume 1,292,600
Day high $1.03 Avg. volume 1,449,177
50-day MA $0.89 Dividend yield N/A
200-day MA $1.20 Market Cap 32.38M

SLS Stock Price Chart Interactive Chart >


SELLAS Life Sciences Group, Inc. (SLS) Company Bio


SELLAS Life Sciences, Ltd. is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications.


SLS Latest News Stream


Event/Time News Detail
Loading, please wait...

SLS Latest Social Stream


Loading social stream, please wait...

View Full SLS Social Stream

Latest SLS News From Around the Web

Below are the latest news stories about SELLAS LIFE SCIENCES GROUP INC that investors may wish to consider to help them evaluate SLS as an investment opportunity.

SELLAS Life Sciences announces launch of proposed public offering

More on SELLAS Life Sciences

SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

- Primary Endpoint of Safety and Efficacy Met with Clinical Activity and Increased Survival Observed - - 70.3 Weeks Median Overall Survival for Patients Treated with Combination Therapy; Median Overall Survival in Relapsed/Refractory Patients Treated with Standard of Care is Approximately 28 Weeks - - Median Overall Survival of Patients without GPS Immune Response was 9.0 Months vs. 27.8 Months for Patients with GPS-Specific Immune Response: a Three-fold or 208.3% Increase in Survival Time - NEW

Yahoo | December 27, 2023

SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas

- SLS009 Demonstrated Promising Efficacy in Phase 1 Study with 36.4% Clinical Response (ORR) in r/r Peripheral T-cell Lymphomas (PTCL); ORR in r/r PTCL Patients with Standard of Care is 25.8% - - One Patient with Complete Metabolic Response Continuing Treatment for over 62 weeks and another patient with Complete Response by CT Continuing Treatment for over 24 weeks - - Phase 1b/2 Study in PTCL Ongoing with top line data expected in 1H 2024 - NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- SELLAS Lif

Yahoo | December 21, 2023

SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia

- Enrollment Completed in 45 mg Safety Cohort; Safety Monitoring Committee Advocated Proceeding to Recommended Phase 2 Dose Level of 60 mg - - Patients in 60 mg Dose Cohort Will be Dosed with 60 mg Once per Week or 30 mg Twice per Week - - Early Data in 45 mg and 60 mg Cohort Expected Around Year-End 2023 - NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the develop

Yahoo | December 14, 2023

SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET

NEW YORK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a corporate update webinar on Wednesday, January 3, 2024, at 8:30 a.m. Eastern Time. Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS, will discuss the Company’s achievements in 2

Yahoo | December 13, 2023

Read More 'SLS' Stories Here

SLS Price Returns

1-mo 0.00%
3-mo -4.72%
6-mo -38.41%
1-year -26.81%
3-year -87.41%
5-year -98.02%
YTD -4.72%
2023 -55.08%
2022 -57.32%
2021 -4.82%
2020 35.12%
2019 -93.01%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!